Logo

Merck Extends License to GeneGo s MetaCore and MetaBase by Two Years

Jan 09, 2006

NEW YORK, Jan. 9 (GenomeWeb News) - Merck has extended its global enterprise agreement with GeneGo for its data-mining suite for two more years, GeneGo said today.

 

Merck researchers will continue to use GeneGo's MetaCore data-mining suite in research and development activities.

 

They will also retain direct access to MetaBase, a database of mammalian protein interactions, signaling and metabolic pathways, bioactive compounds, and diseases manually curated by GeneGo from full text experimental literature.

 

MetaCore and MetaBase have been integrated with Merck's discovery informatics platform and are used across multiple therapeutic areas.

 

Financial details were not disclosed.

Breaking News
The Scan

Booster for At-Risk

The New York Times reports that the US Food and Drug Administration has authorized a third dose of the Pfizer-BioNTech SARS-CoV-2 vaccine for people over 65 or at increased risk.

Preprints OK to Mention Again

Nature News reports the Australian Research Council has changed its new policy and now allows preprints to be cited in grant applications.

Hundreds of Millions More to Share

The US plans to purchase and donate 500 million additional SARS-CoV-2 vaccine doses, according to the Washington Post.

Nature Papers Examine Molecular Program Differences Influencing Neural Cells, Population History of Polynesia

In Nature this week: changes in molecular program during embryonic development leads to different neural cell types, and more.